Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com

origin: oncology genomic testing

A portfolio of Exact genomic solutions that delivers actionable insights on treatment determination and therapy selection to inform personalized decisions.

We're defining a new approach to oncology genomics.

Exact Sciences’ Precision Oncology Portfolio of Tests

Raise your Exactations

with genomic information for each patient’s situation.

FOR PATIENTS

Genomic testing can help inform the right cancer treatment decision for you

It's important to know everything you can about genomic tests; that way, you and your doctor can make an informed decision together.

Learn more about genomic testing

Real patients share their stories of inspiration

  • Meet Deepa

    A surgeon diagnosed with node negative, invasive breast cancer who used the Oncotype DX Breast Recurrence Score test to help inform a decision to not get chemotherapy.

  • Amy's Oncotype DX Breast DCIS Score Story

    Amy, a breast cancer survivor, describes her experience using Genomic Health's Oncotype DX DCIS Breast Cancer Score to personalize her treatment options. Share this video with your loved ones to help empower other women facing a DCIS (ductal carcinoma in situ) breast cancer diagnosis to ask for personalized treatment. For more information, please visit: www.genomichealth.com www.oncotypedx.com

  • Lloyd and His Wife Discuss Prostate Cancer Treatments and Active Surveillance

    When it comes to prostate cancer, communication is vital, not only with a patient's doctor, but with their partner as well. We join Lloyd and his wife as they, with the help of Dr. Ketan Badani, learn that surgery and radiation are not the only treatment options.

Billing & Coverage

Exact Sciences believes that everyone should have access to the information they need to make informed decisions about their cancer treatment. That’s why we offer the Genomic Access Program (GAP) to help patients navigate the insurance and billing process.

We’ve set the Exactations high

Over 1 million patients benefited from Oncotype DX® tests


Helping them avoid over/undertreatment in breast, prostate, and colon cancers.